Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes
Click here to read the study in Annals of Internal Medicine ©2025 2 Minute Medicine, Inc. All rights ...
Tag: SGLT2i
#VisualAbstract: Sodium–Glucose Co-Transporter-2 (SGLT2) Inhibitors Do Not Improve Survival Free of Organ Support in COVID-19
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Beneficial effects found with combined usage of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors
1. Compared with using only using a GLP-1 receptor agonist or an SGLT-2 inhibitor, combination therapy with both drug classes ...
Higher doses of heart failure guideline-directed medical therapy prescribed to patients with acute heart failure admission are associated with better outcomes
1. Higher doses of guideline-medical therapy (GDMT) within 2 weeks after discharge from an acute heart failure (AHF) admission were ...
Sodium-glucose cotransporter-2 inhibitors may decrease incidence of recurrent gout flares
1. Over a one-year period, the incidence of recurrent gout flares in patients with gout and diabetes was significantly lower ...
2 Minute Medicine Rewind July 3, 2023
Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial 1. In this randomized controlled trial, it was found ...
Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis
1. Sodium-glucose co-transporter-2 inhibitor (SGLT2i) use was associated with a decreased risk of in-stent restenosis (ISR) related major adverse cardiac ...
Sodium-glucose cotransporter 2 inhibitors may reduce incidence of respiratory events in Type 2 diabetics
1. In this retrospective cohort study, patients with Type 2 Diabetes (T2D) using sodium-glucose cotransporter 2 inhibitors (SGLT2is) were found ...
Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
1. Among patients with type 2 diabetes in Hong Kong, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) can reduce ...
Empagliflozin use is associated with slower progression of chronic kidney disease
1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...